Kết quả hoá xạ trị đồng thời tiền phẫu trong ung thư trực tràng trung bình giai đoạn tiến triển tại chỗ=Outcomes of preoperative concurrent chemoradiotherapy in locally advanced middle rectal cancer

0 Người đánh giá. Xếp hạng trung bình 0

Tác giả: Vinh Quang Bùi, Thị Tuyết Hoàng, Thị Kim Phượng Trần

Ngôn ngữ: vie

Ký hiệu phân loại:

Thông tin xuất bản: Tạp chí Y học Việt Nam (Tổng hội Y học Việt Nam), 2024

Mô tả vật lý: tr.194-201

Bộ sưu tập: Metadata

ID: 478139

Thêm vào giỏ

Đánh giá đáp ứng và một số tác dụng không mong muốn của phác đồ hóa xạ trị đồng thời tiền phẫu trong ung thư trực tràng trung bình giai đoạn tiến triển tại chỗ. Đối tượng và phương pháp nghiên cứu: Nghiên cứu mô tả thực hiện trên bệnh nhân (BN) được chẩn đoán xác định ung thư trực tràng trung bình giai đoạn tiến triển tại chỗ tại bệnh viện Ung Bướu Hà Nội và bệnh viện Trung ương Thái Nguyên giai đoạn từ 6/2018 – 5/2023. Kết quả: 53 bệnh nhân được lựa chọn vào nghiên cứu. Tuổi trung bình của nhóm nghiên cứu là: 64,9 ± 10,5, tỷ lệ nam/nữ là 1,2:1. Tỷ lệ bệnh nhân cải thiện triệu chứng cơ năng từ 70 - 100%. Tỷ lệ đáp ứng toàn bộ sau điều trị là 42/53 (79,3%) bệnh nhân, trong đó có 1 (1,9%) bệnh nhân đáp ứng hoàn toàn. Tác dụng không mong muốn chủ yếu gặp độ 1-2. Một số tác dụng không mong muốn thường gặp bao gồm: hạ bạch cầu 13 (24,5%) BN
tiêu chảy 19 (35,8%) BN, viêm niêm mạc ống hậu môn-trực tràng 10 (18,9%) BN, hội chứng bàn tay, bàn chân 10 (18,9%) BN. Kết luận: Hóa xạ trị đồng thời tiền phẫu (Capecitabine + 3D-CRT/IMRT) trên bệnh nhân ung thư trực tràng trung bình giai đoạn tiến triển tại chỗ cho thấy hiệu quả cao, an toàn, các tác dụng không mong muốn chủ yếu ở mức độ nhẹ.To evaluate the response and side effects of preoperative concurrent chemoradiotherapy (CCRT) in locally advanced middle rectal cancer. Subjects and Methods: The descriptive study conducted on patients diagnosed with locally advanced middle rectal cancer at Hanoi Oncology Hospital and Thai Nguyen Central Hospital from June 2018 to May 2023. Results: 53 patients were enrolled. Their average age was: 64.9 ± 10.5, and the male/female ratio was 1.2:1. The rate of patients with improved functional symptoms was 70- 100%. The overall response rate after treatment was 42/53 (79.3%) patients, of which 1 (1.9%) patient had complete response. The main side effects were at grade 1-2. Some common side effects included leukopenia (13 patients - 24.5%)
diarrhea (19 patients - 35.8%), proctitis and anusitis (10 patients - 18.9%), and hand-foot syndrome (10 patients - 18.9%). Conclusion: Preoperative concurrent chemoradiotherapy (Capecitabine + 3DCRT/ IMRT) in patients with locally advanced middle rectal cancer demonstrated high efficacy, and safety, most side effects were mild.

1. Đọc trực tuyến

1. Đọc trực tuyến

Tạo bộ sưu tập với mã QR